[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559267":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":10,"centralContacts":10,"locations":31,"responsibleParty":57,"collaborators":10,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Normal control",null,"Subjects without memory complaints and associated worries and do not meet the diagnostic criteria for mild cognitive impairment (MCI) are recruited as normal control (NC).",[13],"Other: Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing",{"label":15,"type":10,"description":16,"interventionNames":17},"Subjective cognitive decline","Subjects who complain of memory decline within the last 5 years and express worries associated with memory decline and do not meet the diagnostic criteria for MCI are defined as subjective cognitive decline (SCD).",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Mild cognitive impairment","Participants are considered MCI patients with scores \\>1 standard deviation (SD) below the normative means in both subtests within one cognitive domain or \\>1 SD below the normative means in three single tests in three different domains.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Alzheimer's disease dementia","Patients are diagnosed as AD dementia by an experienced neurologist based on MMSE and CSF\u002FPET biomarker evidence.",[13],[27],{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing","Multimodal magnetic resonance imaging scanning, including 3DT1, 3DT2, 3DFLAIR, functional MRI, DTI, NODDI, ASL, QSM behavioral testing, such as olfaction and spatial navigation genetic testing, such as APOE, BDNF plasma biomarker testing, such as ptau, Aβ42\u002F40、NfL、GFAP",[23,19,9,15],[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Nanjing Drum Tower Hospital","RECRUITING","Nanjing","Jiangsu","210008","China","CN",{"type":41,"coordinates":42},"Point",[43,44],118.77778,32.06167,{"lat":44,"lon":43},[47,52,54],{"name":48,"role":49,"phone":50,"phoneExt":10,"email":51},"Bing Zhang, PhD","CONTACT","15851803070","zhangbing_nanjing@nju.edu.cn",{"name":48,"role":53,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"name":55,"role":56,"phone":10,"phoneExt":10,"email":10},"Qian Chen, PhD","SUB_INVESTIGATOR",{"type":58,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100559267","establish-diagnostic-and-prognostic-models-for-preclinical-ad-patients-based-on-multimodal-mri-behavioral-genetic-and-plasma-biomarkers-100559267",false,"NCT06561906","Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers","Inclusion Criteria:\n\n* The inclusion criteria were 50-79 years old and having 8 or more years of education.\n\nExclusion Criteria:\n\n* Participants with a history of stroke, other neurological disorders that could lead to cognitive impairment (Parkinson's disease, encephalitis, epilepsy, brain tumors, etc.), severe anxiety or depression, and contraindications for magnetic resonance imaging (MRI) were not enrolled.",true,"ALL","50 Years","79 Years",{"count":70,"type":71},1000,"ESTIMATED","OBSERVATIONAL","To establish the diagnostic and prognostic models that could help the preclinical identification of subjects at higher risk of clinical progression to mild cognitive impairment and dementia based on combined features of baseline demographic, cognitive, behavioral, multimodal MRI, genetic, and plasma data.",[75,76,77],"Alzheimer Disease, Late Onset","Mild Cognitive Impairment","Subjective Cognitive Decline",[79,80,81,82,83],"magnetic resonance imaging","spatial navigation","olfaction","genetic","plasma biomarkers","2024-08-16",{"date":86,"type":87},"2024-08-20","ACTUAL",{"date":89,"type":87},"2020-09-01",{"date":91,"type":71},"2027-12",{"name":5,"class":6},1]